Scinai Immunotherapeutics Stock Market Value
| SCNI Stock | USD 0.97 0.06 5.83% |
| Symbol | Scinai |
Is there potential for Stock market expansion? Will Scinai introduce new products? Factors like these will boost the valuation of Scinai Immunotherapeuti. If investors know Scinai will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Scinai Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Scinai Immunotherapeutics requires distinguishing between market price and book value, where the latter reflects Scinai's accounting equity. The concept of intrinsic value—what Scinai Immunotherapeuti's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Scinai Immunotherapeuti's price substantially above or below its fundamental value.
Please note, there is a significant difference between Scinai Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scinai Immunotherapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Scinai Immunotherapeuti's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Scinai Immunotherapeuti 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Scinai Immunotherapeuti's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Scinai Immunotherapeuti.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Scinai Immunotherapeuti on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Scinai Immunotherapeutics or generate 0.0% return on investment in Scinai Immunotherapeuti over 90 days. Scinai Immunotherapeuti is related to or competes with Onconetix, Scisparc, Azitra, Indaptus Therapeutics, Biomotion Sciences, Jasper Therapeutics, and Revelation Biosciences. Scanner Technologies Corporationration engages in the development and marketing of machinevision inspection solutions that are used in the semiconductor industry for the inspection of integrated circuits. More
Scinai Immunotherapeuti Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Scinai Immunotherapeuti's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Scinai Immunotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 38.82 | |||
| Value At Risk | (9.29) | |||
| Potential Upside | 11.65 |
Scinai Immunotherapeuti Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scinai Immunotherapeuti's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Scinai Immunotherapeuti's standard deviation. In reality, there are many statistical measures that can use Scinai Immunotherapeuti historical prices to predict the future Scinai Immunotherapeuti's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.45) | |||
| Total Risk Alpha | (0.86) | |||
| Treynor Ratio | (0.15) |
Scinai Immunotherapeuti January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 5.41 | |||
| Coefficient Of Variation | (2,340) | |||
| Standard Deviation | 7.47 | |||
| Variance | 55.85 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.45) | |||
| Total Risk Alpha | (0.86) | |||
| Treynor Ratio | (0.15) | |||
| Maximum Drawdown | 38.82 | |||
| Value At Risk | (9.29) | |||
| Potential Upside | 11.65 | |||
| Skewness | (0.06) | |||
| Kurtosis | 2.52 |
Scinai Immunotherapeutics Backtested Returns
Scinai Immunotherapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0427, which indicates the firm had a -0.0427 % return per unit of risk over the last 3 months. Scinai Immunotherapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Scinai Immunotherapeuti's Risk Adjusted Performance of (0.02), variance of 55.85, and Coefficient Of Variation of (2,340) to confirm the risk estimate we provide. The entity has a beta of 2.25, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Scinai Immunotherapeuti will likely underperform. At this point, Scinai Immunotherapeutics has a negative expected return of -0.32%. Please make sure to validate Scinai Immunotherapeuti's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Scinai Immunotherapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.43 |
Average predictability
Scinai Immunotherapeutics has average predictability. Overlapping area represents the amount of predictability between Scinai Immunotherapeuti time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Scinai Immunotherapeutics price movement. The serial correlation of 0.43 indicates that just about 43.0% of current Scinai Immunotherapeuti price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.43 | |
| Spearman Rank Test | 0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Currently Active Assets on Macroaxis
When determining whether Scinai Immunotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scinai Immunotherapeuti's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scinai Immunotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scinai Immunotherapeutics Stock:Check out Scinai Immunotherapeuti Correlation, Scinai Immunotherapeuti Volatility and Scinai Immunotherapeuti Performance module to complement your research on Scinai Immunotherapeuti. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Scinai Immunotherapeuti technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.